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Access to essential medicines is both a fundamental basic right and necessity for everyone, 
thus governments should make concerted efforts to ensure that all have access to safe, quality 
and comparative cost-effective medicines. Efforts aimed at identifying factors hindering full 
access are key in informing relevant policy makers. Thus in pursuant of making significant 
contributions to the above, a survey was carried-out in Harare metropolitan province of 
Zimbabwe to determine prices, price components, pricing policies, source and availability of 
essential medicines (their innovator and/or generic equivalents) in both private and public retail 
sectors. Comparisons with 36 other low to middle-income countries in the rest of Africa, 
Americas, Eastern Mediterranean, Europe, Southeast Asia and Western Pacific were also 
conducted. A standardized methodology developed by World Health Organization and Health 
Action International (WHO/HAI) was used to survey a selected basket of 40 medicines. The 
selection was based on the WHO/HAI core medicines list and the latest version of the essential 
drug list of Zimbabwe. The survey was conducted in 110 private pharmacies, of which 55 were 
from the central business district, 33 from the high density and 22 from the low density suburbs. 
In both private and public sectors, availability of the selected essential medicines (low priced 
generics) was quite high (>80%).  Fewer innovator brands were found for the selected 
medicines. Median price ratios (MPR) of the lowest priced generics revealed that many people 
still might be having their accesses to essential medicines compromised by high prices, 
particularly in the private sector (4.52). The public sector showed significant progress towards 
procurement efficiency (MPR of 1.5). More than 70% of the surveyed medicines were from 
manufacturers outside Zimbabwe with more than 60% being produced by Indian generic 
manufacturers. Zimbabwe still needs to do more on pricing, particularly in the private sector 
as well as promoting local production among other efforts in its quest to ensure all its people 
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1.1. Background to and rationale for this study 
This chapter discusses the background and rationale for price and availability surveys of 
essential medicines particularly, in low and middle income countries like Zimbabwe. The 
World Bank (2013), notes that while in most parts of the world people are growing older than 
ever before and much progress done on prevention of child deaths sub-Saharan Africa still has 
significant challenges with communicable, maternal, nutritional, and newborn diseases. As 
noted sub-Saharan Africa has a worryingly high disease burden, with controllable infectious 
diseases contributing more than 69% of all deaths and a rapidly increasing non-communicable 
or chronic disease burden (contributing more 25% of deaths) (Kebede et al, 2010; Lawn and 
Kinney, 2009 and Young et al, 2010). Thus millions in the region are suffering serious 
complications and/or dying from manageable diseases like cholera, malaria, haemorrhagic 
fevers, HIV, diabetes, hypertension, etc. (Kebede et al, 2010; Lawn and Kinney, 2009 and 
Young et al, 2010). This epidemiological picture makes access to basic quality, safe and 
effective pharmaceutical care of paramount importance. Generally medicine availability and 
prices are significant determinants of access to basic pharmaceutical care. According to 
WHO/HAI (2008) at least 50% of people in poor third world countries in Africa and Asia have 
limited access to basic pharmaceutical care. WHO (2004) as cited by Cameron et al (2008) 
suggests that up to 90% of populations in third world countries like Zimbabwe use out-of-
pocket cash payments for essential medicines making basic healthcare spending by households 
a significant expenditure. Given this observation, Zimbabwe’s high unemployment level and 
economic challenges may significantly complicate access to basic medicines. 
The economic situation has the ability to significantly affect availability of crucial medicines 
in both health sectors (i.e. public and private sectors) and affordability. The economic 
challenges and the high levels of out-of-pocket payments for healthcare has the ability to create 
even more vulnerable groups requiring protection leading to a potentially deadly vicious cycle. 
According to T’Hoen (2003) high prices of medicines are a significant barrier to essential 
medicines to many people. Higher prices are often associated with innovator/brand products as 
a result of intellectual property protection among other costs as compared to generic products 
(T’Hoen, 2003). Also fewer manufacturers are in brand medicine production as compared to 
those in generics hence any medicine available in a generic form is more likely to be way 
cheaper and more available. Thus generic medicines are more accessible to the general public, 
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so a pharmaceutical policy encouraging generic stocking and prescribing will enhance access 
to quality, safe and effective medicine. Comparing prices and policies/practices with 
international benchmarks allows the researcher to gather evidence, thus aiding policy makers 
to craft policy that will enhance medicine access and public health in general. Also the survey 
will assist policy makers in coming-up with various protection mechanisms that will ensure 
that all have access to basic healthcare. Assessing prices and various pricing policies in both 
public and private practices will also allow the nation to harmonize these policies for the 
betterment of all and further protection to the poor and other vulnerable groups. According to 
the Directorate of Pharmacy services in the Ministry of Health and Child Care (MoHCC), 
formerly Ministry of Health and Child Welfare (2011) Zimbabwe is not only faced with 
significant essential medicine shortages but also inadequate pharmaceutical professionals 
particularly in the public sector. Taking consideration of both sectors is based on the 
understanding that private sector often penetrates communities better as compared to the public 
sector hence better policies in private sector has immense potential in enhancing access to 
essential medicines. Thus this cross-sectional survey is not only going to assist in answering 
the researcher’s research questions but also inform policy makers and other stakeholders 
determining access to medicines. 
1.2. Aim 
The main aim of this survey is to document and compare availability and prices of basic 
pharmaceuticals (innovator and their generic equivalents) in private and public health sectors 
in the Harare Province, Zimbabwe and compare the results with those in other countries. 
1.3. Objectives: 
To: 
 Determine final retail prices charged to healthcare consumers on basic medicines (based 
on WHO/HAI and the Essential Medicine List of Zimbabwe) in both private and public 
pharmacies in Harare province, Zimbabwe relative to international prices. 
 Compare levels of availability and prices of essential innovator products and their 
generic equivalents in both private and public health sectors. 
 Determine the common sources of the selected essential medicines in both sectors.  
 Determine the different price components and pricing policies in both private and 






1.4. Novelty and significance of this study 
In Zimbabwe, there is a dearth of information on prices or availability of essential medicines 
accessible for facilitation of policy formulation. With current trends in policy formulation 
utilizing evidence based methods/approaches, studies like this one need to be done often and 
on a national scale to assist in ensuring that formulators of the pharmaceutical policy have 
access to relevant evidence. Essential medicines have a central role in primary health care 
hence public health assurance. Various issues hinder access like prices and whether the 
medicines are available or not in the nearest retail outlet or primary health care centre. Surveys 
of this nature also inform policy makers on fairness and equality in pharmaceutical care thus 
promoting access to care for all as health is everyone’s basic right.  
1.5. Overview of this thesis 
Chapter 2: Explores how sub-Saharan African countries, Zimbabwe in particular have a high 
disease burden hence demand for essential medicines. It also highlight issues to do with 
essential medicines and access to quality, safe and effective medicines. 
Chapter 3: Describes surveys and their significance in social science research. Application of 
surveys in price and availability surveys. 
Chapter 4: Contains the submitted manuscript which outlines the whole study. The article was 
submitted to the African Journal of Primary Health Care & Family Medicine, Ref. No.: 1088. 
Chapter 5: Contains additional findings on availability and median price ratios of essential 
medicines surveyed. It also features comparisons of median price ratios across and within 
sectors. 
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2.1. Disease burden in sub-Saharan Africa: Zimbabwe  
Zimbabwe is a low-income country in the sub-Saharan region of Africa (The World Bank, 
2016). Many low-income countries in sub-Saharan Africa have a very high disease burden with 
chronic diseases becoming more and more important each year (The World Bank, 2013; 
Cooper et al, 1998). According to de-Graft Aikins et al (2010) Africa which is the arguably the 
poorest continent virtually has a double burden of both infectious and chronic diseases.  More 
than 69% of all deaths are as a result of infectious diseases and age-specific mortality due to 
chronic diseases is higher in sub-Saharan Africa than the rest of the world (de-Graft Aikins et 
al, 2010). Due to low or non-functioning health infrastructure (Cooper et al, 1998), 
maldistribution of healthcare resources (Agere, 1990) and shortage of key healthcare personnel 
the statistics are expected to get worse as the population in the continent continues to grow. 
Actually de-Graft Aikins et al (2010) in their article predicted a marked increase in deaths due 
to cardiovascular disease, cancer, respiratory disease and diabetes. The region has the highest 
mortality rate for children under 5 years. Zimbabwe is part of a few countries which have 
actually seen an increase in this rate (UNESCO, 2008).  
According to WHO (2014) communicable, maternal, perinatal and nutritional conditions 
contributed 62% of all deaths followed by cancers at 10% and cardiovascular diseases (9%) in 
Zimbabwe. With a prevalence of HIV/AIDS just under 15% (Zimbabwe Country Report, 
2015), it will be expected that HIV/AIDS is underlying in many of the disease noted by WHO 
(2014).  Actually currently HIV/AIDS is the number one contributor to Zimbabwe’s age-
standardized death rate followed by stroke, respiratory diseases, coronary heart diseases, 
tuberculosis, malaria, diarrhoeal diseases then diabetes mellitus among other top 50 killers 
(MoHCC, 2015). Despite many efforts to combat HIV/AIDS since the first case was discovered 
in Zimbabwe in 1985, it is still a major contributor to the healthcare burden (Garbus and 
Khumalo-Sakutukwa, 2003). HIV/AIDS has led to many deaths across all age groups and 
genders. At one point it was predicted that Zimbabwe would have the world’s lowest life 
expectancy (Garbus and Khumalo-Sakutukwa, 2003 and UNESCO, 2008). Generally 
HIV/AIDS is a serious problem in sub-Saharan Africa, AVERT (2015) estimates that in 2013 
the region had “24.7 million people living with HIV, accounting for 71% of the global total.” 
The high disease burden in Zimbabwe and the whole of sub-Saharan Africa means that many 
significant efforts required to address this public health issue. This is true given most of the 
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said deaths are preventable through improved availability and access to basic health services 
and child nutrition programmes (UNESCO, 2008). From this analysis Zimbabwe has great 
need for quality, safe and effective essential medicines. Thus access to medicines like 
antiretrovirals becomes key in prevention and management (AVERT, 2015).  
2.2. Essential medicine concept  
The World Health Organization, (2015) defines essential medicines as; 
“those that satisfy the priority health care needs of the population” and “are selected 
with due regard to disease prevalence, evidence on efficacy and safety, and 
comparative cost-effectiveness.”  
Thus they should be;  
“available within the context of functioning health systems at all times in adequate 
amounts, in the appropriate dosage forms, with assured quality, and at a price the 
individual and the community can afford” – World Health Organization, (2015). 
Zimbabwean National Medicine Policy (ZNMP) similarly defines essential medicines as; 
“those medicines, which are of the greatest importance, are basic, indispensable 
and needed to satisfy the health needs of the majority of the population” – 
Directorate of Pharmacy Services, (2011).  
The concept is noble and implementation should be flexible and adaptable to each specific 
country’s context. The concept is based on the understanding that it is not possible to have a 
full spectrum of all medicines thus countries can have a limited range of carefully selected 
essential medicines that will lead to better health care, better medicine management and lower 
costs (Laing, 2012). Zimbabwe has also adopted the essential medicines concept, with regularly 
publication of the Essential Drug List of Zimbabwe (EDLIZ). The main objective of EDLIZ is 
to ensure that health care needs of all Zimbabweans are met through the provision and proper 
use of essential medicines (NMTPAC, 2011).  
The selection of medicines that are included in EDLIZ is based on; 
 Relevance to prevalent diseases 
 Proven efficacy and safety 
 Adequate scientific data in a variety of settings 
 Adequate quality 
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 Favourable cost-benefit ratio 
 Desirable pharmacokinetics 
 Possibilities for local manufacture 
 Available as single ingredient items (NMTPAC, 2011) 
In the Zimbabwean context the NMTPAC (2011) highlights several advantages for utilizing 
the essential medicine concept namely; 
 Improved medicines supply due to easier supply chain management among other 
reasons. 
 More rational prescribing – more focussed training of all healthcare professionals, 
better experience and more information when dealing with fewer options among other 
reasons.  
 Lower costs – fewer options leads to more competition thus greater opportunities of 
getting cheaper options.   
 Improved patient use (NMTPAC, 2011). 
As stated in its ZNMP, Zimbabwe through the utilization of the essential medicine concept has 
an overall objective of improving, within the available resources, the health of the majority of 
the population of Zimbabwe by treating, curing, reducing or preventing diseases and/or 
disorders of health through medicine procurement, promotion of local production of essential 
medicines, management and use (Directorate of Pharmacy Services, 2011). 
Noting many benefits the essential medicine concept brought since its inception and description 
as “a peaceful revolution in international public health” in 1977 the concept has also faced 
some criticisms. Often criticism comes from issues to do with who actually judges the 
importance on a particular disease, the patient suffering or providers and intellectual property 
rights like patents (Laing et al, 2003).  
From the analysis it is vital that people have access to the specially selected medicines for 
healthcare objectives to be met. Actually everyone by international law has the right to health. 
Many factors however may hinder access essential medicines which are key in ensuring health 
for all (Hogerzeil and Mirza, 2011). Factors which limit access to essential medicines include, 
availability and prices (i.e. affordability).  United Nations Development Group (2003) defines 
access “as having medicines continuously available and affordable at public or private health 
facilities or medicine outlets that are within one hour’s walk from the homes of the population.”  
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2.3. Prices of essential medicines  
High essential medicines prices decrease affordability and have a negative impact on low 
income countries such as Zimbabwe and many other sub-Saharan countries particularly those 
with less government control on medicine pricing (Murray, 2015). Medicines have the ability 
to significantly consume a big portion of the healthcare budget particularly in developing 
and/or transitional countries where they account for 20–60% of all healthcare spending (WHO, 
2004 as cited by Cameron et al, 2008). Also many in these countries rely on out-of-pocket 
payments for their pharmaceutical among other healthcare needs. Actually the World Health 
Organization (2004) as cited by Cameron et al, (2008) states that up to 90% of the population 
in developing countries purchase medicines through out-of-pocket payments. Thus high prices 
have a significant negative impact on access to essential medicines as many may “choose” to 
forgo treatments or look for other alternatives which may be not be as effective or safe. As 
essential medicines are public goods and not luxury goods that should be reserved for the rich, 
their prices must not become major barriers to access and healthcare advancements.   
2.4. Availability of essential medicines  
Availability of essential medicines is also key in ensuring that people have access to one of the 
key components of primary healthcare (PHC). Healthcare consumers should be able to 
purchase and/or get essential medicines as and when they are required (UN, 2011). In many 
developing countries access to essential medicines is hindered because many people rely on 
public health dispensing facilities which often do not have enough (UN, 2011). As noted above, 
medicine availability is often a challenge in many low-income countries like Zimbabwe 
particularly in the public sector (Murray, 2015). The said low availability is often attributed to;  
 Lack of systematic procurement, supply and distribution systems  
 Under-budgeting  
 Poor demand forecasting and management among other reasons (UN, 2011; Murray, 
2015). 
Generally prices are lower in the public sector but availability is often very low as compared 
to the private sector thus both prices and availability can be major issues in determining access 
to essential medicines.  Apart from lack of enough essential medicines the pharmaceutical 
market is now flooded with “fake” or counterfeit medicines that are killing many (WHO, 2006). 
Counterfeiting is one of the oldest profession and has invaded many pharmaceutical markets 
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world-over. (Fenoff and Wilson, 2009). The World Health Organization, (2006), estimated that 
the counterfeit medicine industry is a multi-million dollar business.  Africa is under threat from 
counterfeit medicines, thus further to availability and price issues many are having access to 
essential medicines hindered due to many counterfeit medicinal products in the African 
pharmaceutical markets (Fenoff and Wilson, 2009).  
2.5. Summary  
Zimbabwe just like many other developing countries in the sub-Saharan Africa region have a 
higher disease burden hence demand for essential medicines. Many factors determine access 
to essential medicines but price and availability are key. Often in low – income countries like 
Zimbabwe the public sector has low availability while the private sector tend to have high 
prices as a result of limited government control on medicine prices. Thus many may have 
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3.1. Surveys  
Surveys are very simple and involve data collection from selected participants based on their 
response to questions, thus describing quantitatively certain characteristics of a given 
population (De Leeuw et al, 2008). The information is usually gathered from a representative 
sample of the population (Fraenkel and Wallen, 1993). Similarly Tanur, (1982) as cited by 
Pinsonneault and Kraemer, (1993) defines a survey as "gathering information about the 
characteristics, actions or opinions of a large group of people, referred to as a population." They 
are conducted for the purposes of making a detailed description, exploration and/or an 
explanation of certain population characters (Burton, 2007). As highlighted above it utilizes a 
representative sample which is derived from a population of elements with equal chances of 
being selected. Surveys are versatile, efficient and generalizable which makes them popular 
with many scientists particularly in social science. Surveys allows researchers to gather unique 
information, use unbiased samples and collect same information from different respondents 
(Owens, 2002). As the goal of carrying-out a survey is to make generalizations, the sample 
should be a true representative of the population. Bartlett et al (2001) highlighted a table to use 














Table 3.1. Determining minimum returned sample size for a given population size for 
continuous and categorical data (Bartlett et al, 2001) 
 
NOTE: The margins of error used in the table were 0.03 for continuous data and .05 for 
categorical data. Researchers may use this table if the margin of error shown is appropriate for 
their study; however, the appropriate sample size must be calculated if these error rates are not 
appropriate. Table developed by Bartlett, Kotrlik, & Higgins (Bartlett et al, 2001). 
In addition to being  compatible with qualitative, quantitative and mixed methods; surveys also 
allow for  both probability and non-probability sampling approaches (Burton, 2007). They can 
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be cross-sectional i.e. data collected at one point in time (a snap-shot) or longitudinal i.e. trend, 
cohort and/or panel surveys (Owens, 2002). Burton (2007) identified characteristics of a good 









3.2. Survey methods  
“A story. In the beginning, there was Quantitative Research. A few years later, 
there was Qualitative Research. And then Mixed Methods was born, as a separate 
child of these parents. Let’s all welcome Mixed Methods” – Creswell and Piano 
Clark (2007) 
Given the weakness and strength of each method i.e. qualitative or quantitative, many scientists 
are now advocating for mixed methods in social science research (Jick, 1979). So in research 
it is best to view qualitative and quantitative methods as complimentary rather than rivals 
contributing to the supremacy of mixed methods approaches (Jick, 1979). Johnson and 
Onwuegbuzie, (2004) has defined mixed methods research as “the class of research where the 
researcher mixes or combines quantitative and qualitative research techniques, methods, 
approaches, concepts or language into a single study”. They went further and highlighted the 
strengths and weaknesses of qualitative (table 3.2 below), quantitative (table 3.3 below) and 







Table 3.2. Strengths and weaknesses of qualitative research  




Data are based on the participants’ own categories of 
meaning. 
Knowledge produced may not generalize to 
other people or other settings (i.e., findings 
may be unique to the relatively few people 
included in the research study). 
Useful for studying a limited number of cases in depth. It is difficult to make quantitative predictions. 
Useful for describing complex phenomena. It is more difficult to test hypotheses and 
theories. 
Provides individual case information. It may have lower credibility with some 
administrators and commissioners of 
programs. 
Can conduct cross-case comparisons and analysis. It generally takes more time to collect the 
data when compared to quantitative research. 
Provides understanding and description of people’s personal 
experiences of phenomena (i.e., the “emic” or insider’s 
viewpoint). 
Data analysis is often time consuming. 
 
Can describe, in rich detail, phenomena as they are situated 
and embedded in local contexts. 
The results are more easily influenced by the 
researcher’s personal biases and 
idiosyncrasies. 
The researcher identifies contextual and setting factors as 
they relate to the phenomenon of interest. 
 
The researcher can study dynamic processes (i.e., 
documenting sequential patterns and change). 
 
The researcher can use the primarily qualitative method of 
“grounded theory” to generate inductively a tentative but 
explanatory theory about a phenomenon. 
 
Can determine how participants interpret “constructs” (e.g., 
self-esteem, IQ). 
 
Data are usually collected in naturalistic settings in 
qualitative research. 
 
Qualitative approaches are responsive to local situations, 
conditions, and stakeholders’ needs. 
 
Qualitative researchers are responsive to changes that occur 
during the conduct of a study (especially during extended 
fieldwork) and may shift the focus of their studies as a result. 
 
Qualitative data in the words and categories of participants 
lend themselves to exploring how and why phenomena 
occur. 
 
One can use an important case to demonstrate vividly a 
phenomenon to the readers of a report. 
 
Determine idiographic causation (i.e., determination of 




Table 3.3. Strengths and weaknesses of quantitative research 











Testing and validating already constructed theories about 
how (and to a lesser degree, why) phenomena occur. 
The researcher’s categories that are used may 
not reflect local constituencies’ 
understandings. 
Testing hypotheses that are constructed before the data are 
collected. Can generalize research findings when the data 
are based on random samples of sufficient size. 
The researcher’s theories that are used may not 
reflect local constituencies’ understandings. 
Can generalize a research finding when it has been 
replicated on many different populations and 
subpopulations. 
The researcher may miss out on phenomena 
occurring because of the focus on theory or 
hypothesis testing rather than on theory or 
hypothesis generation (called the confirmation 
bias). 
Useful for obtaining data that allow quantitative 
predictions to be made. 
Knowledge produced may be too abstract and 
general for direct application to specific local 
situations, contexts, and individuals. 
The researcher may construct a situation that eliminates the 
confounding influence of many variables, allowing one to 
more credibly assess cause-and-effect relationships. 
 
Data collection using some quantitative methods is 
relatively quick (e.g., telephone interviews). 
 
Provides precise, quantitative, numerical data.  
Data analysis is relatively less time consuming (using 
statistical software). 
 
The research results are relatively independent of the 
researcher (e.g., effect size, statistical significance). 
 
It may have higher credibility with many people in power 
(e.g., administrators, politicians, people who fund 
programs). 
 
It is useful for studying large numbers of people.  
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Table 3.4. Strengths and weaknesses of mixed research 
Strengths Weaknesses 
Words, pictures, and narrative can be used to add 
meaning to numbers. 
Can be difficult for a single researcher to carry out 
both qualitative and quantitative research, especially 
if two or more approaches are expected to be used 
concurrently; it may require a research team. 
Numbers can be used to add precision to words, 
pictures, and narrative. 
Researcher has to learn about multiple methods and 
approaches and understand how to mix them 
appropriately. 
Can provide quantitative and qualitative research 
strengths. 
Methodological purists contend that one should 
always work within either a qualitative or a 
quantitative paradigm. 
Researcher can generate and test a grounded 
theory. 
More expensive. 
Can answer a broader and more complete range of 
research questions because the researcher is not 
confined to a single method or approach. 
More time consuming. 
A researcher can use the strengths of an additional 
method to overcome the weaknesses in another 
method by using both in a research study. 
Some of the details of mixed research remain to be 
worked out fully by research methodologists (e.g., 
problems of paradigm mixing, how to qualitatively 
analyse quantitative data, how to interpret conflicting 
results). 
Can provide stronger evidence for a conclusion 
through convergence and corroboration of 
findings. 
 
Can add insights and understanding that might be 
missed when only a single method is used. 
 
Can be used to increase the generalizability of the 
results. 
 
Qualitative and quantitative research used together 
produce more complete knowledge necessary to 
inform theory and practice. 
 
Adapted from Johnson and Onwuegbuzie, (2004). 
3.3. Price and availability surveys 
Surveys collecting both qualitative and quantitative data on essential medicines using the 
standardised World Health Organisation and Health Action International (WHO/HAI) 
methodologies have been used in several price, affordability and availability studies in several 
regions of the world (Mhlanga and Suleman, 2014; Madden et al, 2010; Russo and McPake, 
2010). In these and other similar studies data was analysed for both generic and originator 
brand products, within  the public and private sector. Several policy options in facilitating 
access to essential medicines in all these regions were influenced by these studies (van Mourik 
et al. 2010). 
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3.4. Summary  
In the quest to ensure all have access to quality, safe and effective pharmaceutical care (i.e. 
primary health care) policy makers are using evidence based approaches in policy formulation. 
Mixed methods price and availability surveys are greatly assisting in devising sound policy 
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Background: Access to essential medicines is both a fundamental basic right and necessity for 
everyone, thus concerted efforts should be made to ensure all have access to safe, quality and 
effective medicines.  
Aim: To determine prices, source and availability of essential medicines (their innovator and/or 
generic equivalents) in both private and public retail sectors.  
Setting: Private and public sector retail pharmacies in Harare metropolitan province, 
Zimbabwe. 
Methods: Forty medicines were selected for the survey. A standardised methodology 
developed by World Health Organization and Health Action International (WHO/HAI) was 
used to survey the selected medicines. The survey was conducted in 110 private pharmacies 
and the two central hospital pharmacies in Harare. Prices were compared with international 
reference prices (IRPs).   
Results: In both sectors, availability of the selected medicines (low priced generics) were quite 
high (>80%).  Fewer innovator brands were found for the selected medicines. Median price 
ratios (MPR) of lowest priced generics (LPG) showed that many still might be having their 
accesses to essential medicines compromised by high prices particularly in the private sector 
(with median MPR of 4.52). The public sector showed significant progress towards 
procurement efficiency (median MPR of 1.5). More than 70% of the surveyed medicines were 
from manufacturers outside Zimbabwe with more than 60% from Indian generic 
manufacturers.  
Conclusion: Zimbabwe still needs to do more on pricing particularly in the private sector, 
promoting local production among other efforts in its quest to ensure all its people have access 





Sondage sur le prix et la disponibilité des produits pharmaceutiques de base et connexes 
dans la province de Harare, Zimbabwe 
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Contexte: L'accès aux médicaments essentiels est à la fois un droit fondamental et une 
nécessité pour tout le monde, donc des efforts concertés devraient être fournis pour assurer que 
chacun ait accès à des médicaments de qualité, sans danger et efficaces.  
Objectif: déterminer les prix, l’origine et la disponibilité des médicaments essentiels (les 
produits innovants et / ou  génériques équivalents) auprès des ventes au détail dans les secteurs 
public et privé.  
Cadre: les pharmacies de vente au détail dans les secteurs privés et publics à Harare province 
métropolitaine de Zimbabwe. 
Méthodologie: Quarante médicaments ont été sélectionnés pour le sondage. Une méthodologie 
standardisée élaboré par l'Organisation mondiale de la Santé et Action Internationale pour la 
Santé (OMS/AIS) a été utilisé pour étudier les médicaments sélectionnés. Le sondage a été 
mené dans 110 pharmacies privées et les deux pharmacies des hôpitaux centraux à Harare. Les 
prix ont été comparés avec les prix de référence internationaux (IRP). 
Résultats: Dans les deux secteurs, la disponibilité des médicaments sélectionnés (des 
génériques à bas prix) était très élevée (> 80%). Nous n’avons trouvé que très peu de marques 
innovatrices pour les médicaments sélectionnés. Les ratios des prix médians (MPR) pour les 
génériques les moins chers (LPG) ont montré que beaucoup aurait accès aux médicaments 
essentiels qui seraient compromis par les prix élevés en particulier dans le secteur privé (avec 
MPR médian de 4,52). Le secteur public a montré des progrès significatifs sur l'efficacité des 
achats (médiane de 1,5 MPR). Plus de 70% des médicaments étudiés étaient fournis par des 
fabricants en dehors de Zimbabwe avec plus de 60%, des fabricants de génériques indiens. 
Conclusion: Zimbabwe doit encore faire plus au niveau prix en particulier dans le secteur privé 
ainsi que dans la promotion de la production locale, entre autres efforts dans sa quête pour 







The concept of essential medicines was introduced by the World Health Organization (WHO) 
in 19771. Their selections is based on their public health relevance, efficacy, quality, safety and 
cost-effectiveness among other reasons. They may be viewed as “medicines that satisfy the 
priority health care needs of the population”1. Because they are of high value to any nation 
their availability and affordability is vital to ensure public health. Sub-Saharan Africa has a 
worryingly high disease burden, with controllable infectious diseases contributing more than 
69% of all deaths and a rapidly increasing non-communicable or chronic disease burden 
(contributing more 25% of deaths) 2, 3, 4. 
 
Zimbabwe had a growing population of more than 14 million people as at 20135. This 
population is also under siege from various chronic and/or acute ailments and poverty (as more 
than 56% live by under a dollar a day)6. Thus Zimbabwe has so many poor people suffering 
from various diseases who need adequate, quality, safe and effective pharmaceutical care.  
Many diseases afflict Zimbabweans, young and old for example human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS), tuberculosis (TB), cardiovascular 
diseases, diabetes, cancers, 5 and malaria, among other ailments. These issues further highlight 
the great need for essential medicines that the Zimbabwean population has. In Zimbabwe 
public healthcare financing and subsequent utilization are dependent on economic growth, thus 
as the economy grows, health is expected to improve7. The Government of National Unity 
brought some economic stability and slight improvements in many sectors including health, in 
Zimbabwe8. Those notable improvements are likely going to be eroded due to the lack of 
political fluency characterising the period post 2013 election. Thus price and availability 
surveys have a lot of potential to assist in the development of contingency measures that ensure 
populations have access to essential medicines by providing key evidence for pharmaceutical 
policy makers. Pricing and/or price surveys are critical in the quest to improve access to quality, 
safe and effective essential medicines9, particularly in low- to medium income countries like 
Zimbabwe. Equitable access to quality, safe and effective essential medicines remains one of 
the most important determinants of the health of many i.e. public health10, particularly in third 
world nations like Zimbabwe. There are levels that can be used to measure and report medicine 
availabilities namely; very low (≤ 50%), low (51 – 65%), fairly high (66 – 80%) and high (80% 
<)10. Cost of pharmaceuticals has been increasing significantly over the years even in 
developed countries leading to higher growth rates in expenditure on medicines even higher 




Surveys done in third world countries have shown very low accessibility to essential medicines. 
Chief among the reasons being the prices people pay as well as availability and poor supply 
chain management.12 These findings further paints a bleak picture for third world countries. 
Surveys comparing the medicine prices against international reference prices (IRP) (i.e. 
affordability) and availability in various sectors based on the World Health Organization and 
Health Action International methodology have been done in many regions, resulting in  
important findings. Although several price and availability surveys have been done in many 
third world countries, Zimbabwe is among the fewer sub-Saharan countries with very little of 
such necessary data13. This study was therefore conducted to determine prices, price 
components, pricing policies, source and availability of essential medicines (their innovator 
and/or generic equivalents) in both private and public retail sectors. A comparison between the 
different sectors and with IRPs was also carried out.     
 
Methods  
Study design  
A mixed methods cross-sectional descriptive survey design was used to collect the data for this 
study.  
Setting and sampling  
The study was conducted in Harare metropolitan province of Zimbabwe with a total human 
population of more than 2.1 million14. Harare is also the capital city of Zimbabwe. The total 
population for this study was made-up of all retail pharmacies (private and public) in Harare 
province, Zimbabwe. In the public sector data on prices and pricing policies is mostly 
centralized thus only retail pharmacies at the only two central government hospitals (Harare 
and Parirenyatwa hospitals) represented all public institutions in this survey. According to 
Medicines Control Authority of Zimbabwe there are about 465 privately owned retail 
pharmacies in and around Harare. Since the pharmacies are not evenly distributed throughout 
Harare, stratified sampling was applied. The sample was made-up of 50% (55 private retail 
pharmacies) from the Central Business District, 30% (33) High Density Suburbs and the 
remaining 20% (22) from Low Density Suburbs of Harare. Back up pharmacies were also 
identified to cater for those with less than 50% medicine availability and/or who would deny 
the researcher access to the information that was being sought for.  
Selection of targeted medicines 
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As shown by table 1 below; 40 medicines were selected for the survey. The selection was based 
on the WHO/HAI global core medicines list6 and the latest version of the Essential Drug List 
of Zimbabwe (EDLIZ). The WHO/HAI core list was established based on availability, 
importance, relevance in addressing overall global disease burden and representativeness. The 
supplementary medicines added were selected based on their relevance to local needs, level of 



















Table 4.1: List of surveyed essential medicines  









Data collection and recording  
Data collection was done between June and August 2015. The researcher visited each 
pharmacy and collected the data on prices and availability using a standardized form6. The final 
Amitriptyline 25mg tablets   Antidepressant  7, 14 or 30 
Amlodipine  10mg tablets   Antihypertensive  30 
Amoxicillin  250mg tablets/capsules   Antibacterial  42 
Artemether/ Lumefantrine 20/120mg tablets Antimalarial  24 
Atenolol  50mg tablets   Antihypertensive  30 
Atropine injectable  Antimuscarinic  1 
Benzathine penicillin injectable  Antibacterial  1 
Carbamazepine 200mg tablets   Antiepileptic  30 
Ceftriaxone injectable   Antibacterial  1 
Chlorpheniramine 5mg tablets  Antihistamine  21 or 30 
Ciprofloxacin 500mg tablets   Antibacterial  10 or 14 
Clindamycin 150mg capsules Antibacterial  42 
Codeine tablets Opioid  15 
Co-trimoxazole   480mg tablets   Antibacterial  60 
Cotrimoxazole 240mg/5ml paed suspension   Antibacterial  100ml 
Diclofenac 25mg tablets   Anti-inflammatory  21 
Digoxin tablets  Cardiotonic glycoside  30 
Doxycycline 100mg capsules Antibacterial  14 
Erythromycin 250mg tablets/capsules Antibacterial  56 
Fluconazole 200mg capsules/tablets Antifungal  30 
Glibenclamide 5mg tablets Antidiabetic  30, 60 or 120 
Halothane gas Anaesthetic  1 
Hydrochlorothiazide 25mg tablets   Antihypertensive  30 
Ketamine injectable Anaesthetic  1 
Lignocaine injectable  Local anaesthetic  1 
Miconazole oral gel Antifungal  40ml 
Nevirapine 10mg/ml pead suspension  Antiviral  100 
Nifedipine 20mg SR tablets   Antihypertensive  30, 60 or 120 
Omeprazole 20mg tablets/capsules Anti-acid   30 
Oxytocin injectable  Hormonal  1 
Paracetamol  500mg tablets   Antipyretic  20 
Paracetamol syrup Antipyretic  100ml 
Pethidine injectable  Opioid  1 
Praziquantel 600mg tablets Anti-schistosomiasis  2, 3, or 4 
Prednisolone 5mg tablets Steroidal anti-inflammatory  30, 60 or 120 
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol 
150/75/400/275 tablets 
Anti-tuberculosis  60 or 90 
Salbutamol inhaler Anti-asthmatic  1 
Tenofovir/ Lamivudine/Effeviranz tablets Antiviral(s)  30 






form used was adjusted accordingly, following a pilot study that was conducted prior to actual 
data collection. The retail price or price charged to the consumer was recorded for each of the 
selected medicines. Data on medicine availability, manufacturer and usually dispensed 
quantities were also collected. Data was collected on both the innovator brand (IB) and lowest 
priced generic (LPG) for all the selected medicines. Double entry technique was used in 
recording the data into a pre-programmed workbook. Data is based on particular dates each 
outlet was visited as this was a cross-sectional survey.  
Statistical analysis  
Statistical analysis was done using the Microsoft excel workbook and Stata statistical package 
with the help of a biostatistician. Median price ratios (MPR) of all the surveyed medicines, 
median MPRs, percentage availabilities and manufacturer’s proportions we generated using 
the mentioned computer softwares. Median price ratio is the median price of each medicine 
divided by the international reference price (IRP). Zimbabwe is currently using United States 
dollar so there was no need currency conversions. The data of availability was based on the 
number of pharmacies that had the medicine on the day that particular pharmacy was surveyed.   
Ethical considerations 
The Humanities & Social Sciences Research Ethics Committee of the University of KwaZulu 
Natal (HSS/0346/015M) and the Pharmacist Council of Zimbabwe approved the research and 
study tools before data were collected. Consent from representatives of each targeted institution 
was sought for before data collection as well. Information was also treated with all necessary 






All the targeted institutions were surveyed in this study.    
Availability of essential medicines 
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Table 2 below compares availability of essential medicines in both private and public sectors 
in the Harare metropolitan province, Zimbabwe. The private sector is further divided into high 
density (HD), central business district (CBD) and low density (LD) suburbs. The availability 
of innovator brands was generally low across the sectors although it can be seen from table 2 
that the low density had somewhat high availability of very few of the selected medicines. The 
public sector had most the medicines selected for the survey, particularly low priced generics. 
A few essential medicines were completely absent in the public sector namely; ciprofloxacin, 
amlodipine, omeprazole, chlorpheniramine, fluconazole, miconazole oral gel and praziquantel. 
Almost all of the medicines used in theatres were completely absent in the private sector. 
Availability of many other selected medicines (low priced generics) in the private sector was 
quite similar (i.e. mean availability in HD was 80%, CBD 77% and LD 85%). Availability of 
medicines in general in the public sector was also high with mean availability of 79%. 
Combining the two sectors, availability of the selected essential medicines (low priced 














Public sector Private sector 
Lowest-price generics Innovator 
brands 
Lowest-price generics Innovator brands 
HD CBD LD HD CBD LD 
Absent  0% Ciprofloxacin, amlodipine, 
omeprazole, 
chlorpheniramine, 
fluconazole, miconazole oral 
gel and praziquantel 
The rest of 
the brands 
surveyed  
Halothane and nevirapine 
susp. 
Halothane, nevirapine 
susp., ketamine and RIPE 
Halothane, ketamine and RIPE The rest of 
the brands 
surveyed 
The rest of 
the brands 
surveyed 
The rest of the 
brands surveyed 
Low  <50% Diclofenac and doxycycline  None  Ketamine, codeine, RIPE and 
oxytocin  
Lignocaine, atropine, 
oxytocin and pethidine 
Lignocaine, nevirapine susp., 
atropine, oxytocin and 
pethidine 
None  None  None  
Fairly high 50-80% RIPE  None  Lignocaine, tenolam-E, 
pethidine, atropine and 
zidolam-N 
Benzathine, erythromycin, 
zidolam-N and codeine 
zidolam-N  Salbutamol 
inhaler 
None  None  







codeine, paracetamol syrup, 
atropine, AL, benzathine, 
ceftriaxone,  clindamycin, 
cotrimoxazole susp., 
glibenclamide, erythromycin, 
salbutamol inhaler, oxytocin, 
zidolam-N, nevirapine susp. 
and prednisolone      
Warfarin 














fluconazole, miconazole oral 
gel, praziquantel, salbutamol 














oral gel, praziquantel, 
salbutamol inhaler and 















miconazole oral gel, 
praziquantel, salbutamol 













Key: AL – Artemether/Lumefantrine 20/120mg tabs; RIPE – Rifampicin/Isoniazid/Pyrazinamide/Ethambutol 150/75/400/275 tabs; tenolam-E – 
Tenofovir/ Lamivudine/Effeviranz tabs and zidolam-N – Zidovudine/Lamivudine/Nevirapine 300/150/200mg tabs. HD – high density suburbs, 
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CBD – central business district and LD – low density suburbs.  
Source of the surveyed essential medicines  
Most medicines in both sectors private retail pharmacy (i.e. CBD, HD and LD) and the public 
sector are generic medicines manufactured by various Indian manufacturers (figure 1 below). 
More than 60% of all the surveyed medicines came from India, local manufacturers had under 
30% and other international manufacturers had approximately10%.   
 













Prices of medicines  
Generally prices in the private sector were higher than those in the public sector (see table 3 
below). Based on table 3 below no significant differences were observed on medicine prices 
within the private retail pharmacy sector i.e. prices in the three subsectors i.e. central business 
district (CBD), high density (HD) and low density (LD). Median price ratio (MPR) of 1.5 found 
in the public sector is close to 1 implying more procurement efficiency.   
Table 4.3: Median price ratio by sector  











Public  1.5 
MPR calculated based on supplier median price as given in the International Drug Price 



















Of the few innovator brands found in the private sector alone the median MPR was found to 
be 8.45 as shown in table 4 below.  
Table 4.4: Median price ratio of Innovator brands (IB)  
Sector  MPR of IB found  
Private  8.45 
Public  - 
IB – innovator brands  
MPR calculated based on supplier median price as given in the International Drug Price 

























Table 5 below presents MPR’s of LPGs of medicines from different pharmacological classes 
by pharmacy sector. Prices of medicines in the private sector ranged from two (2) times to even 
more than 4 times that of the same medicine in the public sector. Some prices in the private 
retail sector were even 10 times high than the international reference prices (IRP).  
Table 4.5: Median price ratios according to pharmacological classes 
Pharmacological class or indication of medicine Sector 
Public Private 
Antidepressant(s) 2.50 6.25 
Antibacterials 1.49 2.82 
Antihypertensives   1.64 4.43 
Anti-inflammatory and pain management    3.51 6.90 
Anti-acid(s)  - 7.78 
Antihistamine(s) - 10.94 
Anti-asthmatic(s) 3.66 4.76 
Antidiabetic(s) 1.16 3.9 
 
Independent t-tests  
Based on the paired t-test carried out, pricing in the HD was significantly different from that 
of the CBD (p < 0.05), with those in the HD slightly higher for some medicines surveyed. 
Pricing in the LD was relatively the highest in most of the medicines surveyed. LD prices were 
significantly different from those of the CBD (p = 0.0214). Differences in prices between the 
private retail sector and the public was significant with those in the private way higher (p = 











Comparing with other countries  
Table 6 below compares MPR of innovator brands, whole surveyed basket of essential 
medicines and specific medicines. It compares the current situation in Harare, Zimbabwe with 
Zimbabwe in 200415 and 36 other low to middle-income countries in the rest of Africa (AFR); 
Americas (AMR); Eastern Mediterranean (EMR); Europe (EUR); Southeast Asia (SEAR) and 
Western Pacific (WPR) as reported in 200816. From the table it can be seen that the current 
situation in Harare paints a better picture as compared to findings of studies done earlier in 
Zimbabwe and other countries. Innovator brands though marginally have seen decreases in 
prices. Lowest priced generics have also seen significantly improvements in-terms of 
availability and lower prices. The public sector have also seen tremendous improvements with 
an MPR of 1.5 now.     
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Table 4.6: Comparison of MPR by OB and LPG 



















(Zimbabwe) in 2015 
Private  8.45 4.52 3.88 2.56 3.90 4.76 
Public  - 1.5 1.73 1.53 1.16 3.66 
Zimbabwe in 2004  Private  9.82 3.35 - - - - 
Public  - 2.57 - - - - 
AFR as reported in 
2008 
Private  62.92 21.23 7.69 22.04 33.87 7.19 
Public - 6.79 5.96 21.07 17.65 3.58 
AMR as reported in 
2008 
Private 52.66 25.21 29.63 53.10 67.56 5.58 
Public  - 3.18 4.55 2.06 3.18 1.82 
EMR as reported in 
2008 
Private  24.54 13.75 14.11 50.47 25.06 3.28 
Public  - 6.88 5.67 13.79 17.97 3.02 
EUR as reported in 
2008 
Private  24.96 8.69 13.78 22.12 12.98 4.05 
Public  - 8.19 10.49 6.79 10.54 3.73 
SEAR as reported in 
2008 
Private  21.28 9.61 22.12 19.22 19.06 4.56 
Public  - 6.84 7.46 19.31 17.65 - 
WPR as reported in 
2008 
Private  34.21 11.25 11.08 32.94 34.59 4.32 
Public  - 11.95 9.32 81.71 56.97 4.64 
N/B: AFR – Africa; AMR – Americas; EMR – Eastern Mediterranean; EUR – Europe; SEAR – Southeast Asia and WPR – Western Pacific. 






Based on informants from the retail pharmacist association (RPA) of Zimbabwe and policy 
documents (like the Zimbabwe National Medicines Policy (ZNMP)) Zimbabwe has a free 
market policy when it comes to medicines pricing and availability particularly in the private 
sector. There are various policy positions and recommendations from various stakeholders 
which are not being enforced. The retail pharmacist association of Zimbabwe has a policy 
position that for antiretrovirals, anticancer and insulins the mark-up charged by retail 
pharmacies should not exceed 25%. For other medicines they recommend a mark-up that does 
not exceed 50%. Retail pharmacies are also “allowed” to charge a professional fee of one 
United States dollar ($1) on all medicines pharmacists handle. Compounding fee is set at $5, 
for very complex compounding; pharmacies are “allowed” to charge extra $5 for every hour 
spent preparing the medicine. For all dangerous drugs or narcotics pharmacists are expected to 
charge an extra dollar as well. Stakeholders also agreed with the findings of this survey in terms 
of level of availability of essential medicines which was found to be above 80% and extent to 
which cheaper Indian produced medicines are flooding our markets (i.e. more than 60%). It is 
government policy that antiretrovirals, cotrimoxazole or other medicines used for prophylaxis 
of opportunistic infections in HIV/AIDS, antimalarial and anti-tuberculosis medicines be 
availed to the public free of charge in the public sector.       
Availability of medicines in both sectors surveyed was found to be high (>80%), which shows 
considerable improvements based on surveys done earlier15 and those done in countries of 
similar settings16. Essential medicine availability is one of the key components of the 
Zimbabwe National Medicines Policy (ZNMP). ZNMP is an integral part of the National 
Health Policy17. On availability of essential medicines ZNMP’s aim is;  
“To ensure the highest possible availability of essential medicines throughout the 
nation, including 100% availability of vital medicines at all times at the primary 
healthcare level.”17 
Based on the findings of this research Zimbabwe may be viewed as had significantly made 
most of the difficult strides towards achieving the above mentioned objective given the 
observed high availability even in the public sector. Noting the virtual absence of innovator or 
originator brands in the public sector it can be concluded that Zimbabwe has also made 
concerted efforts to meet its other objective on generic medicines stated below.  
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“To provide safe and effective medicines of acceptable quality at a reasonable price 
to the public through the procurement of generic pharmaceutical products and the 
promotion of their use.” 17  
However Zimbabwe appears to still have much work to do on promoting local production given 
more than 70% of all the medicines surveyed we produced by foreign companies outside 
Zimbabwe. Also cheaper generics produced in India (more than 60% of the surveyed medicines 
were from India) though good in terms keeping prices relatively lower might be hindering local 
production. Both the public and private sectors are overly relying on Indian produced lowest 
priced generics. This is despite ZNMP having another objective of promoting local production;  
“To promote cost effective production of medicines within Zimbabwe in accordance 
with the standards of current Good Manufacturing Practices (cGMP).” 17 
The MPR of 1.5 in the public sector points to significant strides that have been made so far 
towards public procurement efficiency. The survey though highlighting progress and 
improvements particularly in the public sector, confirms that prices of medicines were still very 
high particularly in the private sector which serve many given its proximity to people. Some 
medicines in the private sector were priced more than 10 times the IRP, highlighting the need 
for clear policy frameworks that will guide pricing of essential medicines in the private sector 
as well. The amenability of the private sector means it will be closer to the people and serves 
many as compared to the public sector. This fact means that despite good developments in the 
public sector, high prices in the private sector significantly compromises affordability hence 
access to essential medicines by many people. This is because the public sector in Harare 
province cannot possibly serve more than 2.1 million people14. Thus high prices in the private 
sector if unaddressed will hinder access to quality, safe and effective medicines of many people 
in Harare and Zimbabwe at large as more than 56% live by under a dollar a day6. 
Strengths and limitations of the study  
The study used already established and accepted tools and benchmarks (i.e. WHO/HAI 
methodology on price surveys and international reference prices). The availability and price 
survey had other similar studies done in other countries or regions of similar settings to 
benchmark with.  The use of standardized methods and having other similar studies to 
benchmark with made comparison also easier. Given currently Zimbabwe is using United 
States dollar there were no complex exchange rate calculations needed.  
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The study was a cross-sectional survey implying the data collected were snapshots which 
makes it difficult to give a clearer picture of the nation and unable to pick trends. Given the 
IPRs are based on procurement or tender prices offered by both not-for-profit and for-profit 
suppliers the ratios might be compromised particularly for the private sector which usually gets 
all its supplies from for-profit suppliers. Also the study focussed on 40 medicines, not even 
alternatives thus the selected medicines might have introduced bias. As they are commonly 
used they might be highly available and with lower prices due to both sectors responding to 
demand and competition. Also because the cross-sectional survey could pick things like 
demand per amount available the availability level might be an over estimate.  
Recommendations  
More comprehensive WHO/HAI based surveys should be done annually. More frequency of 
these surveys; including many sectors and regions of the country will give a better picture on 
what the people of Zimbabwe are accessing and paying for their essential medicine needs (i.e. 
affordability).  
The findings of the study shows that Zimbabwe has made some effort towards implementing 
some provisions of its national medicine policy (ZNMP), but more efforts are needed in 
promoting local production and clear pricing policies or laws that affect even the private sector. 
There is also need to further pursue efficiency in procurement and generic medicine usage.  
Conclusions  
High prices particularly in the private sector calls for more efforts to be done to ensure many 
people have access to essential medicines. Actions that could be taken include price 
ceiling/controls, single exit prices, abolishing professional or dispensing fees and many more. 
For access and affordability to be linked with more economic development there is need to 
promote local production while keeping prices of essential medicines low.  More efforts still 
needs to be done to fully implement and realized all the benefits of ZNMP and sustaining the 
positives noted.  
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Additional results  
This chapter outlines other results and interpretations derived from the findings of this study.  
5.1. Sources of medicines   
Availability of medicines was generally high in both sectors being 80% or better. Most 
medicines found were low priced generics that are mostly produced by Indian manufacturers 
(see figure 5.1 below).  
 












5.2. Median price ratios 
A comparison of prices within the private sector, revealed that though they were very similar 
it can be seen in figure 5.2. below that pharmacies in the central business district (CBD) were 
generally lower followed by those from the high density (HD) pharmacies. Low density (LD) 
pharmacies generally had high prices as compared to others within the private sector. This can 
be attributed to relative distribution of pharmacies with the CBD having more of the private 
pharmacies in Harare province, followed by HD then the LD. Also since many people stay in 
HD the relatively high prices as compared to the CBD are possibly a result of pharmacies 
responding to high demand and less competition.  
 










The private sector had prices that were generally more than three (3) times more than those in 
the public sector (see figure 5.3. below). With fewer public sector pharmacies in Harare 
province, many people may still be having their access to quality, safe and effective medicines 
hindered by higher prices despite high availability. Private pharmacies have high penetration 
into people communities as compared to public sector outlets, thus higher prices noted in the 
sector have significant impact on access to essential medicines.  
 
Figure 5.3: Box and whisker plot comparing median price ratios (MPR) of private and 
public sectors 
Median MPR of 1.5 in the public sector underscores significant improvements in the public 
sector procurement, in-terms of its efficiency.  
5.3. Conclusion  
Generic medicines from India might be significantly limiting local production as they seem to 
be the most abundant in the Harare pharmaceutical market. But these products might also have 
significantly contributed to low prices and procurement efficiency particularly in the public 










Conclusions and future recommendations  
This chapter outlines the general conclusion of the study as well as recommendations for future 
research based on its findings. 
6.1. General Conclusion 
High prices particularly in the private sector calls for more efforts to be done to ensure many 
people have access to essential medicines. For access and affordability to be linked with more 
economic development there is need to promote local production while keeping prices of 
essential medicines low.  More efforts still needs to be done to fully implement and realized all 
the benefits of ZNMP and sustaining the positives noted.  
6.2. Recommendations and future studies  
More comprehensive WHO/HAI based surveys should be done annually. More frequency of 
these surveys; including many sectors and regions of the country provide a better picture on 
what the people of Zimbabwe are accessing and paying for their essential medicine needs (i.e. 
affordability).  
The findings of the study shows that Zimbabwe has made some effort towards implementing 
some provisions of its national medicine policy (ZNMP) particularly during its government of 
national unity (GNU) era, but more efforts are needed in promoting local production and clear 
pricing policies that affect even the private sector. There is also need to further pursue 






























































Appendix 7: Assessment of price and availability form  
Number A B C D E F G H I J 
Generic name, 
dosage form and 







Manufacturer Availability  
“yes” or 
“no” 














1 Amitriptyline 25mg 
tabs   
Brand         
Generic          
2 Amoxicillin  
250/500mg 
tabs/caps   
Brand         
Generic          
3 Atenolol  50mg tabs   Brand         
Generic          
4 Nifedipine 20mg 
SR tabs   
Brand         
Generic          
5 Carbamazepine 
200mg tabs   
Brand         
Generic          
6 Diclofenac 50mg 
tabs   
Brand         
Generic          
7 Ciprofloxacin 
500mg tabs   
Brand         
Generic          
8 Tenofovir/ 
Lamivudine/ 
Effeviranz  tabs   
Brand         
Generic          
9 Amlodipine  10mg 
tabs   
Brand         
Generic          
10 Paracetamol  500mg 
tabs   
Brand         
Generic          
11 Hydrochlorothiazide 
25mg tabs   
Brand         
Generic          
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12 Co-trimoxazole   
480mg tabs   
Brand         
Generic          
13 Halothane gas Brand         
Generic         
14 Lignocaine inj Brand         
Generic         
15 Ketamine inj Brand         
Generic         
16 Codeine tabs Brand         
Generic         
17 Pethidine inj Brand         
Generic         
18 Paracetamol syrup Brand         
Generic         
19 Omeprazole 20mg 
tabs/caps 
Brand         
Generic         
20  Chlorpheniramine 
5mg tabs  
Brand         
Generic         
21 Atropine inj Brand         




Brand         
Generic         
23 Benzathine 
penicillin inj 
Brand         
Generic         
24 Ceftriaxone inj  Brand         
Generic         
25 Clindamycin 150mg 
caps 
Brand         
Generic         
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26 Cotrimoxazole  
240mg/5ml paed  
Susp.  
Brand         





Brand         
Generic         
28  Doxcycline 100mg 
caps 
Brand         
Generic         
29 Erythromycin 
250mg tabs/cap 
Brand         
Generic         
30 Fluconazole 200mg 
cap/tabs 
Brand         





Brand         
Generic         
32 Miconazole oral gel Brand         
Generic         
33 Praziquantel 600mg 
tabs 
Brand         
Generic         
34 Warfarin 5mg tabs Brand         
Generic         
35 Digoxin tabs  Brand         
Generic         
36 Salbutamol inhaler Brand         
Generic         
37 Oxytocin inj Brand         




Brand         




10mg/ml pead susp 
Brand         
Generic         
40 Prednisolone 5mg 
tabs 
Brand         





















Generic name, dosage form and strength private public cbd hd ld IRPS
Amitriptyline 25mg tabs  0.045 0.018 0.0545 0.045 0.0655 0.0072
Amoxicillin  250mg tabs/caps  0.0714 0.0318 0.0714 0.0705 0.0775 0.0184
Atenolol  50mg tabs  0.05 0.015 0.045 0.055 0.045 0.0103
Nifedipine 20mg SR tabs  0.1 0.0456 0.092 0.1 0.1 0.025
Carbamazepine 200mg tabs  0.1 0.054 0.1 0.1 0.1 0.0194
Diclofenac 25mg tabs  0.05 0.0468 0.0513 0.05 0.055 0.0056
Ciprofloxacin 500mg tabs  0.11 0.066 0.13 0.2 0.1 0.043
Tenofovir/ Lamivudine/Effeviranz tabs 1 0.00033 0.975 1.033 0.1 0.3857
Amlodipine  10mg tabs  0.2 0.0948 0.198 0.232 0.2 0.0765
Paracetamol  500mg tabs  0.04 0.01799 0.035 0.05 0.02 0.0045
Hydrochlorothiazide 25mg tabs  0.025 0.0138 0.0225 0.0337 0.02 0.0043
Co-trimoxazole   480mg tabs  0.035 0.02304 0.0377 0.035 0.0355 0.0124
Halothane gas 0.312 0.125
Lignocaine inj 0.15 0.078 0.132 0.15 0.15 0.025
Ketamine inj 0.5 0.096 1.7 0.1171
Codeine tabs 0.23 0.12 0.23 0.3 0.215 0.0712
Pethidine inj 1.5 0.321 1.35 1.5 1.4 0.3847
Paracetamol syrup 0.03 0.006 0.03 0.03 0.0175 0.0054
Omeprazole 20mg tabs/caps 0.14 0.14 0.114 0.173 1 0.018
Chlorpheniramine 5mg tabs 0.0175 0.12 0.024 0.438 0.0016
Atropine inj 1 0.78 0.83 0.8 1 0.1435
Artemether/ Lumefantrine 20/120mg tabs 0.417 0.000417 0.38 0.417 2 0.1703
Benzathine penicillin inj 0.3 0.12 0.3 0.3 0.3 0.2635
Ceftriaxone inj 0.3 0.072 0.3 0.3 0.18 0.747
Clindamycin 150mg caps 0.188 0.1196 0.18 0.2 0.03 0.0833
Cotrimoxazole 240mg/5ml paed susp. 0.03 0.012 0.03 0.0275 0.02 0.0051
Glibenclamide 5mg tabs 0.0265 0.00792 0.0255 0.033 0.089 0.0068
Doxcycline 100mg caps 0.1065 0.0883 0.128 0.106 0.0141
Erythromycin 250mg tabs/cap 0.12 0.0551 0.112 0.1255 0.4 0.0391
Fluconazole 200mg cap/tabs 0.4 0.016 0.3143 0.431 0.4 0.0706
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol 150/75/400/275 tabs0.000015 0.0614
Miconazole oral gel 0.125 0.0628 0.125 0.125 0.2 0.0991
Praziquantel 600mg tabs 0.8 0.0472 0.665 1 0.167 0.1199
Warfarin 5mg tabs 0.22 0.1439 0.1964 0.285 0.3 0.0979
Digoxin tabs 0.125 0.0528 0.13 0.12 1.75 0.0121
Salbutamol inhaler 0.05 0.0384 0.05 0.2 0.342 0.0105
Oxytocin inj 1.75 0.39 1.2 1.8 1.75 0.175
Zidovudine/Lamivudine/Nevirapine 300/150/200mg tabs 0.35 0.000167 0.342 0.4 0.34 0.1423
Nevirapine 10mg/ml pead susp 0.143 0.0001 0.135 0.15 0.0101
Prednisolone 5mg tabs 0.033 0.03534 0.031 0.045 0.03 0.0117
